KDventures: Umecrine Secures NCE protection to 2042, unlocking broader commercial upside - Redeye

KDventures announced that its portfolio company Umecrine Cognition has received two notices of allowance from the USPTO for its second-generation GAMSA compounds, GR3053 and GR3055. This creates a pipeline potential for Umecrine.

Länk till analysen i sin helhet: https://www.redeye.se/research/1184477/kdventures-umecrine-secures-nce-protection-to-2042-unlocking-broader-commercial-upside?utm_source=finwire&utm_medium=RSS